Placeholder

R&D Business Models

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge.

Pharmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing technology to an increasingly global environment.
Companies are looking for solutions, but industry experts say the answer may lie in the R&D business model. A report by PricewaterhouseCoopers released earlier this year predicts that by 2020 the old business model — where companies employ a strategy of placing big bets on a few molecules — will no longer meet the market’s needs.
The industry, PricewaterhouseCoopers’ experts say, is undergoing a period of disruptive innovation.
Companies will need to join forces with a wide range of organizations, from academic institutions, hospitals, and technology providers to companies offering compliance programs, nutritional advice, stress management, physiotherapy, exercise facilities, health screening, and other such services.

Digital Exclusive Partnerships Key To Improving Global R&D Model
Access Demo Best Practices for Improving Clinical Performance
Access Demo Better Standards and Metrics for CROs and Sponsors
Access Demo Charting a New Course by Catalyzing Transformation
Access Demo Connecting Through Electronic Health Records
Access Demo The Evolution of the E-Patient
Access Demo Global Clinical Trials Outsourcing: New Tips and Trends
Access Demo Return On Investment in Patient Recruitment
Access Demo Science is Greater than the Economy
Access Demo Best Practices for Improving Clinical Performance
Access Demo In a Tight Economy: The Five Most Critical Clinical Research Factors
Access Demo Leveraging Online Social Media for Clinical Trial Patient Recruitment
Access Demo Predictive Modeling in Clinical Trial Enrollment
Access Demo Rebalancing of Risk to Transform Cost and Productivity in Drug Development
Access Demo Oncology Market Access Europe: Bridging the Gap Between Regulatory Approval and Product Adoption
Access Demo Adaptive Outsourcing Model
Access Demo Combining Medical Imaging with EDC
Access Demo CRA Training
Access Demo CROs Differentiation
Access Demo Data Mining
Access Demo EDC’s Impact
Access Demo Risk Management
Access Demo Strategic Project Management

Sidebars:
Offshoring Trends
Clinical Approval Success Rates by Therapeutic Class 1993-2004
FDA Ratings of Therapeutic ­Significance for Follow-on Drugs Approved in the U.S., 1960–2007
How to Evaluate a CRO
Sound Bites From The Field

Jesse Bowden is President of Imaging Services at Biomedical Systems
Alistair Macdonald is Executive VP, Global Services, at INC Research
Joseph Pieroni is President and CEO, Daiichi Sankyo Inc
Chris Bode, Ph.D., is VP Corporate Development at Absorption Systems LP,
Tony Chant is Managing Director of Eurocom Healthcare Communications
Robert Dickinson is Client Service Officer of the Life Sciences Practice at Grail Research
Sylvia Miriyam Findlay is Programme Leader, Pharmaceutical and Biotechnology, Healthcare, Europe, at Frost & Sullivan
Michael J. Harte is Founder and President of the Harte Group
A. Shabeer Hussain is ­Programme Leader, ­Pharmaceutical and ­Biotechnology, Healthcare, EIA, at Frost & Sullivan
Jan-Anders Karlsson, Ph.D., is CEO of S*BIO Pte Ltd
Nicholas Landekic is President and CEO of PolyMedix Inc
John MacPhee is President of Strativa ­Pharmaceuticals, the proprietary products division of Par Pharmaceutical Inc.
Ken Ribotsky is President and CEO of The Core Nation Inc
Nagaraja Srivatsan is Head of Life Sciences, North America, at Cognizant Technology Solutions
Jason Stowe is CEO of Cycle Computing
Daniel Zurr, Ph.D. is CEO and President, Quark ­Pharmaceuticals Inc.

Experts on this topic
Robert Baltera. CEO, Amira ­Pharmaceuticals Inc., a small-molecule ­pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. For more ­information, visit amirapharm.com.
Stephen Cutler, Ph.D. Senior VP and Chief ­Operating Officer, Kendle, a global ­clinical research organization providing a full range of early- to late-stage clinical development services. For more information, visit kendle.com.
Karen Ferrante, M.D. Senior VP, Clinical, Millennium: The Takeda Oncology Company, a biopharmaceutical company. For more information, visit millennium.com.
Astrid Frank. General Manager, Fisher Clinical Services, Basel, Switzerland, facility, which offers services to support the ­continuum of supply chain needs within a clinical trial setting. For more information, visit fisherclinicalservices.com.
Glen Giovannetti. Global Biotechnology Leader, Ernst & Young, a global provider of assurance, tax, transaction, and advisory ­services. For more ­information, visit ey.com.
Glenn Gormley, M.D., Ph.D. President, Daiichi Sankyo Pharma Development, the product ­development arm of Daiichi Sankyo Inc., which is engaged in clinical development, translational medicine and clinical pharmacology, ­regulatory affairs and risk management, ­informatics ­biostatistics and data operations, and ­development research. For more information, visit dsi.com/research/pharmadev.html.
Laurie Halloran. President and CEO of Halloran Consulting Group, a life-sciences consulting firm specializing in enhancing the development process for biopharmaceutical and medical-device companies. For more information, visit hallorancg.com.
John M. Hudak. President and Founder, ­Criterium Inc., a global, full-service, and ­technology-driven CRO. For more information, visit ­criteriuminc.com.
Jason Hwang, M.D. Executive Director, Healthcare, Innosight Institute, a nonprofit think tank. For more information, visit
innosightinstitute.org.
Jan-Anders Karlsson, Ph.D. CEO, S*BIO Pte Ltd., which is focused on the discovery and clinical development of novel targeted small-molecule drugs for the treatment of cancer. For more information, visit sbio.com.
Carolyn Buck Luce. Global Pharmaceutical Leader, Ernst & Young, a global provider of ­assurance, tax, transaction, and advisory ­services. For more information, visit ey.com.
John Potthoff, Ph.D. Chief Operating Officer, INC Research, a therapeutically focused global CRO. For more information, visit incresearch.com.
Sanjay Parikh, Ph.D. Director, Indegene, a provider of transformational services including scientific content, creative services, and business intelligence solutions. For more information, visit indegene.com.
James R. Weston. Senior VP, Talaris ­Advisors LLC, which provides solutions for drug, diagnostic, and device development worldwide. For more ­information, visit ­talarisadvisors.com or e-mail jweston@talarisadvisors.com.
Steve Worland. President and CEO, Anadys Pharmaceuticals, a ­biopharmaceutical company dedicated to improving patient care by ­developing novel medicines for the treatment of ­hepatitis C. For more information, visit ­anadyspharma.com.

FEEDBACK